Poolbeg Pharma (POLB) Ord Shares
![](https://online.hl.co.uk/img/hl/layout/security-up-arrow.gif)
- Add to watchlist
- Create an alert
- This stock can be held in a
![](https://online.hl.co.uk/img/hl/layout/security-up-arrow.gif)
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
![](https://online.hl.co.uk/img/hl/layout/security-up-arrow.gif)
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
Share news, reports & tips
-
Poolbeg agrees 12-month option over potential Behcet's treatment
30 April 2024 16:43
(Sharecast News) - Poolbeg Pharma announced an exclusive 12-month option agreement with Silk Road Therapeutics on Tuesday, to potentially acquire a novel topical muco-adherent formulation of Pentoxifylline...
-
Poolbeg Pharma to be granted US patent
20 March 2024 11:10
(Sharecast News) - Biopharmaceutical company Poolbeg Pharma announced on Wednesday that it has received a notice of allowance from the US Patent Office regarding its immunomodulator II patent application.
-
Director dealings: Poolbeg Pharma co-founder ups stake
19 February 2024 14:22
(Sharecast News) - Poolbeg Pharma revealed on Monday that chairman Cathal Friel had acquired 830,000 ordinary shares in the AIM-listed biopharmaceutical company.
-
Poolbeg upbeat on research into potential drug market
12 February 2024 14:37
(Sharecast News) - Biopharmaceutical company Poolbeg Pharma announced findings from independent research confirming a substantial market opportunity exceeding $10bn for its drug candidate POLB 001 on Monday,...
-
Poolbeg makes promising progress with RSV programme
20 December 2023 13:54
(Sharecast News) - Poolbeg Pharma revealed promising results from the lab-based analysis and prioritisation of respiratory syncytial virus (RSV) drug targets and treatments on Wednesday, driven by its...
-
Poolbeg gets notice of a new Japan patent
20 September 2023 12:16
(Sharecast News) - Clinical-stage biopharmaceutical company Poolbeg Pharma announced the receipt of a notice of allowance from the Japanese Patent Office for its Immunomodulator I patent application on...
-
Poolbeg reports progress with oral vaccine development
22 June 2023 14:47
(Sharecast News) - Clinical-stage biopharmaceutical company Poolbeg Pharma updated the market on its oral vaccine programme on Thursday.
-
Poolbeg expands its focus molecule into oncology
16 January 2023 15:48
(Sharecast News) - Poolbeg Pharma announced the strategic expansion of 'POLB 001' into oncology on Monday.
-
Poolbeg identifies new drug candidates with OneThree
21 December 2022 13:37
(Sharecast News) - Biopharmaceutical company Poolbeg Pharma has successfully identified potential new drug candidates from its respiratory syncytial virus (RSV) artificial intelligence (AI) programme with...
-
Poolbeg secures exclusive licence to possible obesity drug tech
14 December 2022 16:14
(Sharecast News) - Infectious disease-focussed biopharmaceutical company Poolbeg Pharma has acquired an exclusive licence from AnaBio sister company InsuCaps, it announced on Wednesday, to use its patented...
-
Poolbeg announces 'breakthrough' in AI drug target programme
8 November 2022 13:06
(Sharecast News) - Infectious disease pharmaceutical developer Poolbeg Pharma announced a "significant breakthrough" in its artificial intelligence (AI) programme with partner OneThree Biotech on...
-
Poolbeg Pharma upbeat on US patent application progress
4 October 2022 14:14
(Sharecast News) - Infectious disease pharmaceutical company Poolbeg Pharma updated the market on its intellectual property (IP) position around 'POLB 001' on Tuesday, which it described as a small...
Company announcements Announcements
-
Holding(s) in Company
12 August 2024 13:28
Poolbeg Pharma
-
Voluntary Delisting from OTCQB Market
26 July 2024 07:00
Poolbeg Pharma
-
Notification of Major Holdings
10 July 2024 07:00
Poolbeg Pharma
-
Change of Registered Address
2 July 2024 07:00
Poolbeg Pharma
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
![Deal now](https://online.hl.co.uk/img/form-buttons/deal-now-button.jpg)
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.